Rapid Read    •   7 min read

FDA Recalls Over 67,200 Power Stick Deodorants Due to Manufacturing Violations

WHAT'S THE STORY?

What's Happening?

The U.S. Food and Drug Administration (FDA) has announced a recall of more than 67,200 Power Stick deodorants due to violations of Current Good Manufacturing Practices (cGMP). The recall affects three specific roll-on antiperspirant deodorants manufactured by A.P. Deauville, a Pennsylvania-based personal care company. These products are distributed across New York state and sold at major retailers such as Walmart, Dollar Tree, and Dollar General. The affected deodorants include Power Stick For Her Roll-On Antiperspirant Deodorant Powder Fresh, Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. Consumers are advised to check the lot numbers on the packaging to determine if their product is part of the recall.
AD

Why It's Important?

This recall is significant as it highlights the importance of adhering to manufacturing standards to ensure product safety and quality. The FDA's action underscores the agency's role in protecting consumers from potentially unsafe products. For A.P. Deauville, the recall could impact its reputation and consumer trust, especially as the company emphasizes its commitment to quality and manufacturing in an FDA-regulated facility. Retailers selling these products may also face logistical challenges in managing returns and refunds, potentially affecting their operations and customer relations.

What's Next?

Consumers who have purchased the affected deodorants are advised to stop using them immediately and contact A.P. Deauville for a refund or return the product to the store where it was purchased. The company has provided contact information for inquiries related to the recall. Retailers will need to manage the recall process, ensuring that affected products are removed from shelves and refunds are processed efficiently. The FDA may continue to monitor the situation to ensure compliance and prevent future violations.

AI Generated Content

AD
More Stories You Might Enjoy